Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.85 |
| ▸ | PDE6C | P51160 | 3/20 | 0.85 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.64 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | PDE1A | P54750 | 2/20 | 0.62 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.62 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | PDE2A | O00408 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.61 |
| ▸ | PDE6D | O43924 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2693448 | 1.00 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL30199753 | 0.95 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL25013469 | 0.95 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL18069561 | 0.94 | PDE5A (0.77) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL28482244 | 0.94 | PDE5A (0.83) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7964961 | 0.94 | PDE5A (0.85) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL28417929 | 0.93 | PDE5A (0.82) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7920627 | 0.93 | PDE5A (0.82) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL7965731 | 0.93 | PDE5A (0.84) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL147337 | 0.92 | PDE5A (1.00) | PDE5APDE6CHDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| EP-4356912-A2 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2024-04-24 | — | — | EP | claimed |
| US-20240115678-A1 | PERSONALIZED MULTIDISCIPLINARY CANCER THERAPY | VELTMEYER JAMES (US) | 2024-04-11 | — | — | US | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20220401541-A1 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | FIBROBIOLOGICS, INC. | 2022-12-22 | — | — | US | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| EP-4051305-A1 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | Figene, LLC (US) | 2022-09-07 | — | — | EP | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| EP-4117629-B1 | COMPOSITIONS AND MEDICAL USE OF NALOXONE | PURDUE PHARMA LP (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250241924-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250025444-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES VIA ADMINISTRATION OF BUNTANETAP AND A PHOSPHODIESTERASE INHIBITOR | ANNOVIS BIO, INC. (US) | 2025-01-23 | — | — | US | disclosed |
| US-20220096387-A1 | SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH LURASIDONE | Vivera Pharmaceuticals Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220062189-A1 | Sublingual Delivery for Mitigation of Side Effects Associated with Sildenafil Citrate | Vivera Pharmaceuticals Inc. (US) | 2022-03-03 | — | — | US | disclosed |
| CN-105920603-B | Treatment of erectile dysfunction and other indications | 战略科学与技术有限责任公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20220023223-A1 | SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH BLONANSERIN | Vivera Pharmaceuticals Inc. (US) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PDE5A 172/4885PDE6C 752/4885HDAC1 1829/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PDE5A 172/4885PDE6C 752/4885HDAC1 1829/4885 |
| US-20250241924-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE6C 21/4885HDAC1 2431/4885 |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE5A 418/4885PDE6C 990/4885HDAC1 299/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PDE5A 172/4885PDE6C 752/4885HDAC1 1829/4885 |
| US-20250025444-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES VIA ADMINISTRATION OF BUNTANETAP AND A PHOSPHODIESTERASE INHIBITOR | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 16/4885HDAC1 2403/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE5A 418/4885PDE6C 990/4885HDAC1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.